YOUR MUST-HAVE
PHYSICIANS’ CANCER CHEMOTHERAPY DRUG MANUAL
IS NOW AVAILABLE FOR YOUR
iPHONE, iPAD, AND ANDROID

TRY IT FREE
FOR 30 DAYS

ALL THE GREAT FEATURES OF THE PRINT BOOK
IN A CONVENIENT APP!

• Includes 10 new agents approved by the FDA within the past year and new indications for several previously approved agents

• Up-to-date indications, drug doses and schedules, toxicities, and special considerations for each agent

• Antiemetic treatment regimens for both acute and delayed nausea/vomiting

• Diagrams of drug structures and pathways for many of the agents

• Includes clinical pharmacology, special considerations, indications, and dosages

• Toxicity and drug–drug interactions

• Chemotherapy regimens for all major cancers

• Includes an overview of the basic principles of cancer drug therapy

Download the Physicians’ Cancer Chemotherapy Drug Manual Mobile App today from iTunes and Google Play for your FREE 30 DAY TRIAL! Learn More at go.jblearning.com/ChemotherapyApp

Source Code: Chu19_FMadd

© Jones & Bartlett Learning, LLC. NOT FOR SALE OR DISTRIBUTION
recommendations on dose, precautions, and contraindications, and determining the appropriate usage in the clinical setting, the health care provider or reader is responsible for determining FDA status of any drug discussed that may have limited availability controlled by the Food and Drug Administration (FDA). When consideration is being given to use of any drug, reading the package insert, and reviewing prescribing information for the most up-to-date information or send an email to specialsales@jblearning.com.

Substantial discounts on bulk quantities of Jones & Bartlett Learning publications are available to corporations, professional associations, and other qualified organizations. For details and specific discount information, contact the special sales department at Jones & Bartlett Learning via the above contact information or send an email to specialsales@jblearning.com.

Copyright © 2019 by Jones & Bartlett Learning, LLC, an Ascend Learning Company
ISBN: 978-1-284-16847-1
ISSN: 1536-0008

All rights reserved. No part of the material protected by this copyright may be reproduced or utilized in any form, electronic or mechanical, including photocopying, recording, or by any information storage and retrieval system, without written permission from the copyright owner.

The content, statements, views, and opinions herein are the sole expression of the respective authors and not that of Jones & Bartlett Learning, LLC. Reference herein to any specific commercial product, process, or service by trade name, trademark, manufacturer, or otherwise does not constitute or imply its endorsement or recommendation by Jones & Bartlett Learning, LLC and such reference shall not be used for advertising or product endorsement purposes. All trademarks displayed are the trademarks of the parties noted herein. Physicians' Cancer Chemotherapy Drug Manual 2019 is an independent publication and has not been authorized, sponsored, or otherwise approved by the owners of the trademarks or service marks referenced in this product.

There may be images in this book that feature models; these models do not necessarily endorse, represent, or participate in the activities represented in the images. Any screenshots in this product are for educational and instructive purposes only. Any individuals and scenarios featured in the case studies throughout this product may be real or fictitious, but are used for instructional purposes only.

The authors, editor, and publisher have made every effort to provide accurate information. However, they are not responsible for errors, omissions, or for any outcomes related to the use of the contents of this book and take no responsibility for the use of the products and procedures described. Treatments and side effects described in this book may not be applicable to all people; likewise, some people may require a dose or experience a side effect that is not described herein. Drugs and medical devices are discussed that may have limited availability controlled by the Food and Drug Administration (FDA) for use only in a research study or clinical trial. Research, clinical practice, and government regulations often change the accepted standard in this field. When consideration is being given to use of any drug in the clinical setting, the health care provider or reader is responsible for determining FDA status of the drug, reading the package insert, and reviewing prescribing information for the most up-to-date recommendations on dose, precautions, and contraindications, and determining the appropriate usage for the product. This is especially important in the case of drugs that are new or seldom used.

Production Credits
VP, Product Management: Amanda Martin
Director of Product Management: Matt Kane
Product Manager: Teresa Reilly
Product Assistant: Anna-Maria Forger
Project Specialist: Molly Hogue
Marketing Manager: Lindsay White
Manufacturing and Inventory Control Supervisor: Amy Bacus
Composition and Project Management: S4Carlisle Publishing Services
Cover Design: Kristin E. Parker
Rights & Media Specialist: John Rusk
Media Development Editor: Shannon Sheehan
Cover Image (Title Page, Chapter Opener): © nopparit/iStock/Getty Images Plus
Printing and Binding: McNaughton & Gun
Cover Printing: McNaughton & Gun

6048
Printed in the United States of America
22 21 20 19 18 10 9 8 7 6 5 4 3 2 1
# Contents

Editors and Contributing Authors vi
Preface vii
Acknowledgments viii

<table>
<thead>
<tr>
<th>CHAPTER 1</th>
<th>Principles of Cancer Chemotherapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Introduction</td>
<td>1</td>
</tr>
<tr>
<td>The Role of Chemotherapy in the Treatment of Cancer</td>
<td>2</td>
</tr>
<tr>
<td>Principles of Combination Chemotherapy</td>
<td>3</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>CHAPTER 2</th>
<th>Chemotherapeutic and Biologic Drugs</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>CHAPTER 3</th>
<th>Guidelines for Chemotherapy and Dosing Modifications</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>CHAPTER 4</th>
<th>Common Chemotherapy Regimens in Clinical Practice</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>CHAPTER 5</th>
<th>Antiemetic Agents for the Treatment of Chemotherapy-Induced Nausea and Vomiting</th>
</tr>
</thead>
<tbody>
<tr>
<td>Index</td>
<td>681</td>
</tr>
</tbody>
</table>

Index 681
Editors

Edward Chu, MD
Professor of Medicine and Pharmacology & Chemical Biology
Stanley M. Marks – OHA Chair in Hematology-Oncology Research
Chief, Division of Hematology-Oncology
Deputy Director
UPMC Hillman Cancer Center
University of Pittsburgh School of Medicine
Pittsburgh, PA

Vincent T. DeVita, Jr., MD
Amy and Joseph Perella Professor of Medicine
Professor of Epidemiology and Public Health
Yale Cancer Center
Yale University School of Medicine
New Haven, CT

Contributing Authors

M. Sitki Copur, MD
Adjunct Professor of Medicine
University of Nebraska
Medical Director, Morrison Cancer Center
Mary Lanning Healthcare
Hastings, NE

Laurie J. Harrold, MD
Staff Medical Oncologist
Clinical Assistant Professor of Medicine
VA Pittsburgh Healthcare System
University of Pittsburgh School of Medicine
Pittsburgh, PA
Preface

The development of effective drugs for the treatment of cancer represents a significant achievement beginning with the discovery of the antimetabolites and alkylating agents in the 1940s and 1950s. The success of that effort can be attributed in large measure to the close collaboration and interaction between basic scientists, synthetic organic chemists, pharmacologists, and clinicians. This tradition continues to flourish, especially as we now enter the world of pharmacogenomics, genomics, proteomics, and other omics science along with the rapid identification of new molecular targets for drug design and development.

In this, our 19th edition, we have condensed and summarized a wealth of information on chemotherapeutic and biologic agents in current clinical practice into a reference guide that presents essential information in a practical and readable format. The primary indications, drug doses and schedules, toxicities, and special considerations for each agent have been expanded and revised to take into account new information that has been gathered over the past year. In this edition, we have included 13 new agents that have all been approved by the FDA within the past year and we have also updated new indications for previously approved agents.

This drug manual is divided into five chapters. Chapter 1 gives a brief overview of the key principles of cancer chemotherapy and reviews the clinical settings where chemotherapy is used. Chapter 2 reviews individual chemotherapeutic and biologic agents that are in current clinical use; these agents are presented in alphabetical order according to their generic name. In this chapter, specific details are provided regarding drug classification and category, key mechanisms of action and resistance, critical aspects of clinical pharmacology and pharmacokinetics, clinical indications, special precautions and considerations, and toxicity. Chapter 3 includes recommendations for dose modifications that are required in the setting of myelosuppression and/or liver and renal dysfunction. Relevant information is also provided highlighting the teratogenic potential of various agents. Chapter 4 presents a review of the combination drug regimens and selected single-agent regimens for solid tumors and hematologic malignancies that are used commonly in daily clinical practice. This section is organized alphabetically by specific cancer type. Finally, Chapter 5 reviews commonly used antiemetic agents and regimens used to treat chemotherapy-induced nausea and vomiting, which is a significant toxicity observed with many of the anticancer agents in current practice.

Our hope remains for this book to continue to serve as both an in-depth reference and an immediate source of practical information that can be used by physicians and other healthcare professionals actively involved in the daily care of cancer patients. This drug manual continues to be a work in progress, and our goal is to continue to provide new updates on an annual basis and to incorporate new drugs and treatment regimens that reflect the rapid advances in the field of cancer drug development.

Edward Chu, MD
Vincent T. DeVita, Jr., MD
Acknowledgments

This book represents the efforts of many dedicated people. It reflects my own personal and professional roots in the field of cancer pharmacology and cancer drug development. It also reaffirms the teaching and support of my colleagues and mentors at Brown University, the National Cancer Institute (NCI), and the Yale Cancer Center. In particular, Bruce Chabner, Paul Calabresi, Robert Parks, Joseph Bertino, and Vince DeVita had a major influence on my development as a cancer pharmacologist and medical oncologist. While at the NCI, I was fortunate to have been trained under the careful mentorship of Carmen Allegra, Bob Wittes, and Bruce Chabner. At Yale, I was privileged to work with a group of extraordinarily talented individuals including Yung-chi Cheng, William Prusoff, Alan Sartorelli, and Vince DeVita, all of whom graciously shared their scientific insights, wisdom, support, and friendship. I would also like to thank my co-author, colleague, mentor, and friend, Vince DeVita, who recruited me to the Yale Cancer Center and who has been so tremendously supportive of my professional and personal career. Special thanks go to my colleagues at Jones & Bartlett Learning for giving me the opportunity to develop this book and for their continued encouragement, support, and patience throughout this entire process. I wish to thank my wife, Laurie Harrold, for her love and patience, for her insights as a practicing medical oncologist, and for her help in writing and reviewing various sections of this book. I would also like to thank my parents, Ming and Shih-Hsi Chu, for their constant love, support, and encouragement, and for instilling in me the desire, joy, and commitment to become a medical oncologist and cancer pharmacologist. Finally, this book is dedicated to our two dogs, Mika and Lexi, who are no longer with us, but who live in our hearts forever, to our two new dogs, Rosie and Allie, and to my two beautiful children, Ashley and Joshua, who have brought great joy and pride to our family and who have shown me the true meaning of unconditional loyalty and love.

Edward Chu, MD